Egetis has submitted a marketing authorisation application for Emcitate® and secured MSEK 462 in financing while entering a licensing agreement with Fujimoto for the drug's development in Japan.

Target Information

Egetis is a biopharmaceutical company dedicated to developing innovative treatments for ultra-rare genetic diseases. The company has recently submitted a marketing authorisation application (MAA) for its lead investigational drug, Emcitate® (tiratricol), aimed at treating MCT8 deficiency, a condition characterized by the inability to properly transport thyroid hormones. The application was validated by the European Medicines Agency (EMA) on October 27, 2023, marking a critical step in the regulatory process.

In addition to the EMA submission, Egetis entered into an exclusive licensing agreement with Fujimoto Pharmaceutical Corporation to develop and commercialize Emcitate in Japan. This agreement aims to streamline the drug's availability in this specific market, which is crucial given the lack of approved therapies for MCT8 deficiency on a global scale.

Industry Overview in Sweden

Sweden boasts a robust biopharmaceutical industry, renowned for its innovation and advanced research institutions. The country supports an environment conducive to drug development, backed by a commitment to healthcare and regulatory fr